Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 7 (3), 218-25

Hypertension Pharmacogenomics: Current Status and Future Directions

Affiliations
  • PMID: 15977418
Review

Hypertension Pharmacogenomics: Current Status and Future Directions

Julie A Johnson et al. Curr Opin Mol Ther.

Abstract

Hypertension is the most common chronic disease in the Western world, and while there are many drug classes from which to choose therapy, only 34% of North Americans currently have their blood pressure controlled. The potential clinical utility of pharmacogenomics in helping to guide antihypertensive drug therapy selection is described. The hypertension pharmacogenetics literature is reviewed, which highlights that only a small fraction of the genes that likely contribute to antihypertensive response have been studied to date. The genes for alpha-adducin (diuretic response), the beta1-adrenergic receptor (beta-blocker response) and angiotensinogen (response to multiple drug classes) are among the genes with the most compelling data (based on replication) as pharmacogenetic candidates. Potential limitations of current studies are also discussed. These include reliance on clinic blood pressure, which is probably a suboptimal response phenotype, and the relatively small sample sizes of most studies to date. Also discussed is the relatively simplistic genetic approach that has been taken, which has focused largely on a single gene or single nucleotide polymorphism within a gene. Multiple ways to overcome these potential limitations are described. Hypertension pharmacogenomics holds tremendous potential for providing a mechanism by which management of hypertensive patients might be improved, and future studies should help move this field towards its clinical potential.

Similar articles

  • Pharmacogenetics of Antihypertensive Treatment
    DK Arnett et al. Vascul Pharmacol 44 (2), 107-18. PMID 16356784. - Review
    Hypertension is a common disorder associated with increased cardiovascular morbidity and mortality. Unfortunately, in the US only about one-third of those who are aware o …
  • Pharmacogenomics and Pharmacogenetics of Hypertension: Update and Perspectives--The Adducin Paradigm
    P Manunta et al. J Am Soc Nephrol 17 (4 Suppl 2), S30-5. PMID 16565244. - Review
    There is a growing literature on the potential prospective use of genome information to enhance success in finding new medicines. An example of a prospective efficacy of …
  • Cardiovascular Pharmacogenomics
    JA Johnson et al. Exp Physiol 90 (3), 283-9. PMID 15778411. - Review
    There is large interpatient variability in the response to drugs, including cardiovascular drugs. Thus, while some patients achieve the desired therapeutic response from …
  • Pharmacogenomics of Hypertension
    PE Cadman et al. Curr Opin Nephrol Hypertens 12 (1), 61-70. PMID 12496668. - Review
    The study of genetic determinants of drug responses, particularly at the pharmacodynamic (drug target/receptor and post-receptor) level, is likely to allow us to more pre …
  • The Future of Antihypertensive Treatment
    ZH Israili et al. Am J Ther 14 (2), 121-34. PMID 17414579. - Review
    Despite progress in recent years in the prevention, detection, and treatment of high blood pressure (BP), hypertension remains an important public health challenge. Hyper …
See all similar articles

Cited by 10 PubMed Central articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback